Company news

Actinogen Medical Limited news in 2017

Actinogen Medical Limited's news releases, calls and decks from 2017, newest first.

View company

Prospectus

December 1, 2017

Early Efficacy & Safety Data Planned for XanADu Trial

November 28, 2017

Placement Fully Funds Completion of XanADu Alzheimers Trial

November 28, 2017

R&D Rebate Received Totalling $1.22 Million

November 14, 2017

Quarterly Update & Appendix 4C

October 30, 2017

Final Major Market Patent Granted for Xanamem

October 10, 2017

First Patient Completes Landmark Alzheimers Disease Trial

September 6, 2017

First UK patient treated in ground-breaking clinical trial

August 15, 2017

June Quarterly Update

July 26, 2017

First US Patients Treated in Landmark Alzheimers Trial

June 21, 2017

First UK Site Goes Live in Global Alzheimers Clinical Trial

May 31, 2017

First Patient Treated in Landmark Alzheimers Clinical Trial

May 15, 2017

March Quarterly Update

April 25, 2017

TGA Regulatory Approval for Alzheimers Phase II Trial

March 7, 2017

Actinogen Medical Financial Results

February 27, 2017

UK Regulatory Approval for Alzheimers Clinical Trial-XanADu

February 9, 2017

Xanamem Research Published in Prestigious Medical Journal

February 8, 2017

Appendix 4C - quarterly

January 22, 2017

FDA Approval to Commence Alzheimers Disease Clinical Trial

January 2, 2017

Decks in 2017